Assignee
ENDOGENA THERAPEUTICS INC
US·5 granted patents·3 pending applications·4 citations·filing 2018–2022
Top patents by PatentIndex Score
8 records- 0189US11844755B2Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2022·Granted Dec 19, 2023·1 cites·12 claims
- 0282US11541039B2Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2020·Granted Jan 3, 2023·1 cites·24 claims
- 0373US10807973B2Compounds for use as therapeutically active substances in the treatment of retinal diseasesENDOGENA THERAPEUTICS INC·Filed 2018·Granted Oct 20, 2020·1 cites·40 claims
- 0471US10752593B2Compounds for use as therapeutically active substances in the treatment of retinal diseasesENDOGENA THERAPEUTICS INC·Filed 2018·Granted Aug 25, 2020·1 cites·38 claims
- 0562US12195452B2N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseasesENDOGENA THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2025·0 cites·19 claims
- 0654US2023365545A1New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0749US2023322749A1New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0843US2022089547A1Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseasesENDOGENA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →